| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price |
|---|---|---|---|---|---|---|---|---|
| CD37 | HOT CD7-H52P4 | Human CD37 Full Length Protein (VLP) | Human | HEK293 | HPLC | $620.00 20ug | ||
| CD37 | Human CD37 Full Length Protein, His,Flag Tag (Detergent) | Human | HEK293 | ![]() | $805.00 20ug | |||
| CD37 | HOT CD7-H52H3 | Human CD37 Protein, His Tag, low endotoxin | Human | HEK293 | ![]() | SDS-PAGE | $395.00 100ug | |
| CD37 | Human CD37 Protein, Fc Tag (MALS verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $360.00 100ug | ||
| CD37 | FITC-Labeled Human CD37 Protein, Fc Tag | Human | HEK293 | ![]() | SDS-PAGE | $330.00 25ug |
| Project Name | Drug Type | Therapeutic Area | Indication | Stage | Rights Area |
|---|---|---|---|---|---|
| CD37+CD22 CAR-T | Cell therapy | Oncology/Cancer | AML | PCC | Global |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Lutetium (177lu) lilotomab satetraxetan | 177Lu-DOTA-HH1 | Phase 2 Clinical | Nordic Nanovector | Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin | Details |
| DS-3790a | DS3790a; DS-3790a | Phase 2 Clinical | Daiichi Sankyo Co Ltd | Hematologic Neoplasms | Details |
| Naratuximab emtansine | IMGN-529; K7153A-SMCC-DM1 | Phase 2 Clinical | Immunogen Inc | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin | Details |
| Debio-1562M | Debio-1562M | Phase 2 Clinical | Debiopharm International Sa | Leukemia, Myeloid, Acute; Neoplasms | Details |
| AGS-67E | AGS-67E | Phase 1 Clinical | Agensys Inc | Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin | Details |
| CAR-37 T cell therapy (Massachusetts General Hospital) | Phase 1 Clinical | Massachusetts General Hospital | Hematologic Neoplasms; Leukemia; Lymphoma; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell | Details | |
| CAR-37 T cells(The General Hospital) | Phase 1 Clinical | The General Hospital Corporation D/B/A Massachusetts General Hospital | Hematologic Neoplasms; Leukemia; Lymphoma; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell | Details | |
| anti-CD19 + anti-CD37 bispecific CAR T-cell therapy (Forevertek Biotechnology/Huazhong University of Science and Technology) | Clinical | Huazhong University Of Science And Technology | Lymphoma, Non-Hodgkin | Details | |
| DS3790 | DS-3790; DS3790 | Clinical | Daiichi Sankyo Inc | Hematologic Neoplasms | Details |